申请人:Edwards Louise
公开号:US20050239788A1
公开(公告)日:2005-10-27
Described herein are compounds with affinity for the 5-HT
6
receptor, which have the general formula I:
wherein: R represents a group of Formula II or Formula III; one of A, B D or E is a N atom, the remainder being CH groups;
R
1
is selected from the group consisting of SO
2
Ar, C(O)Ar, CH
2
Ar and Ar;
R
2
, R
3
and R
4
are independently selected from the group consisting of H and alkyl;
represents a single or double bond, with the proviso that there is only one double bond in the ring at a time; n is an integer of from 1-3;
Z is selected from the group consisting of C, CH and N, provided that when
is a double bond, Z is C and when
is a single bond, Z is selected from CH and N; Ar is an optionally substituted aryl group;
with the proviso that when R is a group of Formula II, R
1
is SO
2
Ar.
Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HT
6
receptor is implicated, such as schizophrenia.
本文描述了具有亲和力的化合物5-HT6受体,其具有一般式I:其中:R代表式II或式III的一个基团;A、B、D或E中的一个是N原子,其余为CH基团;R1从SO2Ar、C(O)Ar、CH2Ar和Ar的组中选择;R2、R3和R4独立地从H和烷基的组中选择;表示单键或双键,但环中只有一个双键;n为1-3的整数;Z从C、CH和N的组中选择,但当为双键时,Z为C,当为单键时,Z从CH和N中选择;Ar是可选取代的芳基基团;条件是当R为式II的基团时,R1为SO2Ar。还描述了这些化合物作为药物的使用,用于治疗5-HT6受体抑制所涉及的症状,如精神分裂症。